BR112014033055A8 - Inibidores seletivos de delta pi3k - Google Patents

Inibidores seletivos de delta pi3k

Info

Publication number
BR112014033055A8
BR112014033055A8 BR112014033055A BR112014033055A BR112014033055A8 BR 112014033055 A8 BR112014033055 A8 BR 112014033055A8 BR 112014033055 A BR112014033055 A BR 112014033055A BR 112014033055 A BR112014033055 A BR 112014033055A BR 112014033055 A8 BR112014033055 A8 BR 112014033055A8
Authority
BR
Brazil
Prior art keywords
pi3k inhibitors
selective
selective delta
methods
delta pi3k
Prior art date
Application number
BR112014033055A
Other languages
English (en)
Other versions
BR112014033055B1 (pt
BR112014033055A2 (pt
Inventor
Dhanapalan Nagarathnam
Meyyappan Muthuppalaniappan
Kumar Venkata Satya Vakkalanka Swaroop
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193752&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014033055(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of BR112014033055A2 publication Critical patent/BR112014033055A2/pt
Publication of BR112014033055A8 publication Critical patent/BR112014033055A8/pt
Publication of BR112014033055B1 publication Critical patent/BR112014033055B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

compostos inibidores seletivos de delta pi3k, composição contendo os mesmos, e uso dos referidos compostos. a presente invenção refere-se a inibidores seletivos de proteínas quinases de delta pl3k tendo um sistema de anel 1h-pirazolo[3,4-d]pirimidina, métodos de preparação, composições farmacêuticas que as contenham e métodos de tratamento e/ou prevenção de doenças ou distúrbios mediados por quinase com eles.
BR112014033055-7A 2012-07-04 2013-07-02 Compostos inibidores seletivos de delta pi3k, composição farmacêutica contendo os mesmos, e uso dos referidos compostos BR112014033055B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
IN2692CH2012 2012-07-04
IN2693/CHE/2012 2012-07-04
IN2693CH2012 2012-07-04
IN2692/CHE/2012 2012-07-04
US201261691561P 2012-08-21 2012-08-21
US201261691586P 2012-08-21 2012-08-21
US61/691,561 2012-08-21
US61/691,586 2012-08-21
PCT/IB2013/055434 WO2014006572A1 (en) 2012-07-04 2013-07-02 Selective pi3k delta inhibitors

Publications (3)

Publication Number Publication Date
BR112014033055A2 BR112014033055A2 (pt) 2017-06-27
BR112014033055A8 true BR112014033055A8 (pt) 2021-09-08
BR112014033055B1 BR112014033055B1 (pt) 2023-01-31

Family

ID=54193752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014033055-7A BR112014033055B1 (pt) 2012-07-04 2013-07-02 Compostos inibidores seletivos de delta pi3k, composição farmacêutica contendo os mesmos, e uso dos referidos compostos

Country Status (32)

Country Link
US (7) US9150579B2 (pt)
EP (2) EP3260455B1 (pt)
JP (2) JP6181173B2 (pt)
KR (2) KR101988079B1 (pt)
CN (2) CN104470923B (pt)
AP (1) AP2015008207A0 (pt)
AR (1) AR091677A1 (pt)
AU (1) AU2013285081B2 (pt)
BR (1) BR112014033055B1 (pt)
CA (1) CA2876995C (pt)
CL (1) CL2014003511A1 (pt)
CO (1) CO7170166A2 (pt)
CY (2) CY1119588T1 (pt)
DK (2) DK3260455T3 (pt)
EA (1) EA028750B1 (pt)
ES (1) ES2647416T3 (pt)
HK (1) HK1209737A1 (pt)
HR (1) HRP20171610T1 (pt)
HU (1) HUE034591T2 (pt)
IL (1) IL236351B (pt)
LT (2) LT3260455T (pt)
MX (1) MX357043B (pt)
MY (1) MY169987A (pt)
PH (2) PH12014502865A1 (pt)
PL (2) PL3260455T3 (pt)
PT (1) PT2870157T (pt)
RS (2) RS58793B1 (pt)
SG (2) SG11201408821SA (pt)
SI (2) SI2870157T1 (pt)
TW (1) TWI598100B (pt)
WO (1) WO2014006572A1 (pt)
ZA (2) ZA201409329B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651682T3 (es) 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Moduladores de cinasa novedosos
WO2012151525A1 (en) * 2011-05-04 2012-11-08 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CN104507922B (zh) * 2012-05-04 2018-02-09 理森制药股份公司 用于制备光学纯的并且任选地经取代的2‑(1‑羟基‑烷基)‑色烯‑4‑酮衍生物的新型方法以及其在制备药物中的用途
US10130635B2 (en) 2012-05-04 2018-11-20 Rhizen Pharmaceuticals Sa Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
CA2876995C (en) * 2012-07-04 2020-10-06 Rhizen Pharmaceuticals Sa Novel selective pi3k delta inhibitors
EP3756686A1 (en) 2012-11-02 2020-12-30 TG Therapeutics Inc. Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
WO2014194254A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
JP6987501B2 (ja) * 2014-05-27 2022-01-05 ライゼン・ファーマシューティカルズ・エスアー 医薬製剤用ｐｉ３ｋデルタ選択的抑制剤の改良形態
KR20170016489A (ko) * 2014-06-27 2017-02-13 리젠 파마슈티컬스 소시에떼 아노님 Pi3 델타 및 감마 단백질 키나제의 선택적 이중 저해제로서 치환된 크로멘 유도체
CR20160600A (es) 2014-07-04 2017-03-07 Lupin Ltd Quinolizione derivados como inhibidores pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20190070183A1 (en) * 2015-11-04 2019-03-07 The Trustees Of Columbia University In The City Of New York Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
KR102325899B1 (ko) * 2016-04-29 2021-11-12 주식회사유한양행 퀴나졸린 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3024123A1 (en) 2016-05-27 2017-11-30 Tg Therapeutics, Inc. Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
MX2019002728A (es) 2016-09-09 2019-08-16 Tg Therapeutics Inc Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
AU2018319538B9 (en) 2017-08-22 2021-05-27 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN108434150B (zh) * 2018-02-09 2020-03-10 天津医科大学总医院 Zstk474用于制备ean治疗药物的应用
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
AU2019297362B2 (en) 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN112601746B (zh) 2018-08-21 2022-09-16 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用
CN112142745B (zh) * 2019-06-27 2023-03-21 杭州和正医药有限公司 一种酪蛋白激酶1ε抑制剂、药物组合物及其应用
CN114127074A (zh) * 2019-07-15 2022-03-01 庄信万丰股份有限公司 无定形乌帕拉尼单甲苯磺酸盐
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
CN114891005B (zh) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 一种乌帕利斯对甲苯磺酸盐的制备工艺
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201882A (ja) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPH08175990A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp Ｐｉ３キナーゼ阻害剤とその製造法
JPH08176070A (ja) 1994-12-19 1996-07-09 Mitsubishi Chem Corp ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
JP2001247477A (ja) 2000-03-03 2001-09-11 Teikoku Hormone Mfg Co Ltd 抗腫瘍剤
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
ATE290882T1 (de) 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
US20040242545A1 (en) 2001-07-26 2004-12-02 Santen Phamaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
US6703414B2 (en) 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6894055B2 (en) 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
BR0213734A (pt) 2001-10-30 2004-10-19 Pharmacia Corp Derivados de carboxamida heteroaromático para o tratamento de inflamação
PL211300B1 (pl) * 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US7846925B2 (en) 2002-07-10 2010-12-07 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
JP2006500327A (ja) 2002-07-10 2006-01-05 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ***の運動性を増大させるための化合物の使用
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7601724B2 (en) 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
CA2522435C (en) 2003-04-24 2011-04-12 Merck & Co., Inc. Inhibitors of akt activity
PE20050338A1 (es) 2003-08-06 2005-05-16 Vertex Pharma Compuestos de aminotriazoles como inhibidores de proteina quinasas
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CN101065016A (zh) 2004-09-24 2007-10-31 詹森药业有限公司 蛋白激酶的抑制剂咪唑并[4,5－b]吡嗪酮
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2008007113A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
FR2882751B1 (fr) 2005-03-04 2007-09-14 Aventis Pharma Sa Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
EP1904449A4 (en) 2005-07-08 2010-07-28 Merck Sharp & Dohme CHECKPOINT KINASE INHIBITORS
RU2008109908A (ru) 2005-08-16 2009-09-27 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2008003173A (es) 2005-09-06 2008-03-18 Smithkline Beecham Corp Compuestos de bencimidazol-tiofeno como inhibidores de plk.
WO2007044813A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
WO2007050380A2 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Tyrosine kinase inhibitors
EA200801716A1 (ru) 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
EP1999135A2 (en) 2006-03-30 2008-12-10 Takeda San Diego, Inc. Kinase inhibitors
CA2650303C (en) 2006-04-26 2015-03-24 F. Hoffmann-La Roche Ag Thienopyrimidine pharmaceutical compounds and their use
CA2650295C (en) 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
JPWO2007132867A1 (ja) 2006-05-15 2009-09-24 杉本　芳一 癌の予防及び治療剤
GB0610243D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
US7605160B2 (en) 2006-08-09 2009-10-20 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
WO2008073785A2 (en) * 2006-12-07 2008-06-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
CL2008001356A1 (es) 2007-05-10 2008-11-14 Smithkline Beecham Corp Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
EP2173338A1 (en) 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
CA2714700C (en) 2008-02-22 2013-07-30 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
MX2010009445A (es) 2008-02-29 2011-05-25 Cylene Pharmaceuticals Inc Moduladores de proteina kinasa.
US20090227575A1 (en) 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
EP2265599B1 (en) 2008-03-04 2013-11-20 Natco Pharma Limited Crystal form of phenylaminopyrimidine derivative
JP2011513419A (ja) 2008-03-06 2011-04-28 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
PE20091617A1 (es) 2008-03-13 2009-11-12 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
CN102036990B (zh) 2008-03-19 2015-09-30 凯姆桥公司 新型酪氨酸激酶抑制剂
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
US8822500B2 (en) * 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
EP2276750A2 (en) 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
US7928248B2 (en) 2008-03-31 2011-04-19 Genentech, Inc. Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
US20110184178A1 (en) 2008-04-16 2011-07-28 Takeda Pharmaceutical Company Limited Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
MX2010011370A (es) 2008-04-16 2010-12-15 Vertex Pharma Inhibidores de fosfatidilinositol 3-cinasa.
PT2355828T (pt) 2008-11-13 2018-07-02 Gilead Calistoga Llc Terapias para malignidades hematológicas
EP2411391A1 (en) * 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
ES2651682T3 (es) * 2009-11-05 2018-01-29 Rhizen Pharmaceuticals S.A. Moduladores de cinasa novedosos
WO2012151525A1 (en) * 2011-05-04 2012-11-08 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CA2876995C (en) * 2012-07-04 2020-10-06 Rhizen Pharmaceuticals Sa Novel selective pi3k delta inhibitors

Also Published As

Publication number Publication date
PT2870157T (pt) 2017-11-27
KR20190064687A (ko) 2019-06-10
JP2017186378A (ja) 2017-10-12
AU2013285081A1 (en) 2015-01-22
US9669033B2 (en) 2017-06-06
IL236351B (en) 2018-01-31
KR20150036083A (ko) 2015-04-07
PH12014502865B1 (en) 2015-02-23
HRP20171610T1 (hr) 2018-03-23
EP2870157B1 (en) 2017-08-30
US20170020881A1 (en) 2017-01-26
ZA201507539B (en) 2017-01-25
DK2870157T3 (da) 2017-11-06
TW201402123A (zh) 2014-01-16
EP3260455A1 (en) 2017-12-27
HUE034591T2 (en) 2018-02-28
PL2870157T3 (pl) 2018-01-31
US20200270258A1 (en) 2020-08-27
CL2014003511A1 (es) 2015-07-10
CO7170166A2 (es) 2015-01-28
AR091677A1 (es) 2015-02-18
KR102216606B1 (ko) 2021-02-17
ES2647416T3 (es) 2017-12-21
EA028750B1 (ru) 2017-12-29
US20170204105A1 (en) 2017-07-20
SI2870157T1 (en) 2018-02-28
PL3260455T3 (pl) 2019-12-31
BR112014033055B1 (pt) 2023-01-31
US20140011819A1 (en) 2014-01-09
JP2015522009A (ja) 2015-08-03
US20210403475A1 (en) 2021-12-30
HK1209737A1 (en) 2016-04-08
LT3260455T (lt) 2019-06-10
SI3260455T1 (sl) 2019-07-31
KR101988079B1 (ko) 2019-06-11
US10072013B2 (en) 2018-09-11
US10570142B2 (en) 2020-02-25
WO2014006572A1 (en) 2014-01-09
DK3260455T3 (da) 2019-06-11
CA2876995C (en) 2020-10-06
JP6181173B2 (ja) 2017-08-16
SG11201408821SA (en) 2015-01-29
JP6416339B2 (ja) 2018-10-31
CA2876995A1 (en) 2014-01-09
US20150361083A1 (en) 2015-12-17
US9475818B2 (en) 2016-10-25
CY1121793T1 (el) 2020-07-31
US20190194206A1 (en) 2019-06-27
RS58793B1 (sr) 2019-07-31
ZA201409329B (en) 2016-08-31
TWI598100B (zh) 2017-09-11
CY1119588T1 (el) 2018-03-07
EP2870157A1 (en) 2015-05-13
IL236351A0 (en) 2015-02-26
PH12014502865A1 (en) 2015-02-23
AP2015008207A0 (en) 2015-01-31
CN109970742A (zh) 2019-07-05
MY169987A (en) 2019-06-19
LT2870157T (lt) 2017-12-11
PH12016500156A1 (en) 2017-04-10
EA201492176A1 (ru) 2015-08-31
RS56494B1 (sr) 2018-01-31
AU2013285081B2 (en) 2017-01-12
EP3260455B1 (en) 2019-03-20
SG10201704048UA (en) 2017-06-29
MX357043B (es) 2018-06-25
US10981919B2 (en) 2021-04-20
CN104470923B (zh) 2019-03-29
PH12016500156B1 (en) 2017-04-10
MX2014015946A (es) 2015-07-17
CN104470923A (zh) 2015-03-25
BR112014033055A2 (pt) 2017-06-27
US9150579B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
BR112014033055A8 (pt) Inibidores seletivos de delta pi3k
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112016024626A8 (pt) compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
BRPI0511616A (pt) compostos
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
GB201104267D0 (en) Pyrrolopyridineamino derivatives
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
DOP2014000127A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
EA201690998A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112012010041A2 (pt) derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10
SV2006002175A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
BR112013008140A2 (pt) "compostos imidazotriazinona".
BR112012022650A2 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112014018795A2 (pt) derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2013, OBSERVADAS AS CONDICOES LEGAIS